L. Pierre, M. Philippe, M. Pharmacie-galénique-alain, M. Chimie-thérapeutique-patrick, M. Jean-louis et al., Chimie physique générale, Biochimie, Biologie moléculaire Jean-Michel SIMON ............................. Economie de la santé

B. Sandrine, B. Mariette, B. Biologie-cellulaire-emmanuelle, . Communication, B. Santé-isabelle et al., Chimie thérapeutique Chimie thérapeutique

B. Ariane, B. Cédric, C. Jean-claude, C. Chimie-générale-et-minérale-igor, C. Chimie-analytique-joël et al., Chimie thérapeutique, Microbiologie clinique Béatrice FAIVRE ??????????????..Hématologie -Génie Biologique

J. Olivier, . Toxicologie, K. Sécurité-sanitaire-francine, L. Pharmacie-galénique-alexandrine, B. Informatique et al., Chimie organique Biophysique

S. Anne, S. Pharmacie-galénique-marie-paule, B. Mycologie, T. Nathalie, T. Santé-publique-gabriel et al., Pharmacie galénique I.1. Classification botanique du millepertuis

I. Composition-chimique-du-millepertuis and .. , 17 III.1. Composés phénoliques, p.17

I. Préparation and .. , 47 III.1, p.47

V. Législation-et-comparaison-de-l-'usage-du-millepertuis-entre-la-france, .. Les-etats-unis, and . .. Indesirables-et-interactions-medicamenteuses, 51 V.1. En, Aux Etats-Unis, vol.53, issue.3, p.55

I. 1. Photosensibilité and .. , 59 I.2. Grossesse et allaitement, Surdosage, p.62

I. Interactions-médicamenteuses, .. Et-de-la-glycoprotéine, and P. , 62 II.1. Interaction médicamenteuse par induction du cytochrome P450, p.63

. Elle-pousse-au-bord, des chemins et des endroits incultes, dans les bois clairs, les haies, les buissons à une altitude inférieure à 1600 mètres (Garnier et al, 1961.

A. Phylogeny and G. , An update of the Angiosperm Phylogeny Group classification for the orders and families of flowering plants : APG II, Botanical Journal of the Linnean Society, vol.141, pp.399-436, 2003.

A. Phylogeny and G. , An update of the Angiosperm Phylogeny Group classification for the orders and families of flowering plants : APG III, Botanical Journal of the Linnean Society, vol.161, pp.105-121, 2009.

S. Boutin, Quotidien Durable. http://quotidiendurable.com/news/le-millepertuis-prozac-naturel Brattström A. Long-term effects of St. John's wort (Hypericum perforatum) treatment, 2010.

J. Bruneton, Pharmacognosie, phytochimie, plantes médicinales, pp.440-445, 1999.

J. Bruneton, Les données de l'évaluation, pp.81-96, 2002.

J. Bruneton, Pharmacognosie, phytochimie, plantes médicinales, pp.523-531, 2009.

V. Butterweck, Mechanism of action of St John's wort in depression : what is known?

L. Chevalier and C. Et-crouzet-segarra, Médicaments à base de plantes, pp.139-140, 2004.

S. Cho, J. Hwang, J. Park, . Black, . Cohosh et al., John's Wort (GYNO-Plus ® ) for

P. Crété, Précis de botanique-Systématique des angiospermes, pp.182-183, 1965.

C. Arthur, The Evolution and Classification of Flowering Plants. Bronx, The New, 1988.

D. Bonneval and P. , Manuel pratique de l'herboriste. Saint-Vincent-sur-Jabron

D. Demarque, J. Jouanny, B. Poitevin, and Y. Et-saint-jean, Pharmacologie et matière médicale homéopathique, pp.207-208, 1993.

J. Dugoua, E. Mills, D. Perri, and G. Koren, Safety and efficacity of St. John's wort (Hypericum) during pregancy and lactation, Can J Clin Pharmacol, vol.13, pp.268-276, 2006.

G. Garnier, L. Bézanger-beauquesne, and G. Et-debraux, Ressources médicinales de la flore française, pp.581-584, 1961.

B. Gurley, A. Swain, D. Williams, G. Barone, and S. Battu, Gauging the clinical significance of P???glycoprotein???mediated herb???drug interactions: Comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics, Molecular Nutrition & Food Research, vol.16, issue.7, pp.772-779, 2008.
DOI : 10.1016/S0944-7113(00)80044-6

P. Hammerness, E. Basch, C. Ulbricht, E. Barrette, I. Foppa et al., St. John???s Wort: A Systematic Review of Adverse Effects and Drug Interactions for the Consultation Psychiatrist, Psychosomatics, vol.44, issue.4, pp.271-282, 2003.
DOI : 10.1176/appi.psy.44.4.271

F. Haramburu, Département, 2010.

. Hypericum-perforatum-monograph, Alternative Medicine Review, pp.318-325, 2004.

H. Imai, T. Kotegawa, K. Tsutsumi, T. Morimoto, N. Eshima et al., The recovery time-course of CYP3A after induction by St John's wort administration, British Journal of Clinical Pharmacology, vol.31, issue.5, pp.701-707, 2008.
DOI : 10.1211/0022357011775974

. Iteipmai, Millepertuis Hypericum perforatum L., Chemillé, Iteipmai publications, 1998.

. Iteipmai, Technique de production Millepertuis, 2000.

D. Karapillai and R. Bellomo, Convulsions associated with an overdose of St John's wort. MJA, pp.213-214, 2007.

A. Karioti and A. Bilia, Hypericins as Potential Leads for New Therapeutics, International Journal of Molecular Sciences, vol.30, issue.Suppl. 1
DOI : 10.1002/ptr.2681

L. Knuppel and K. Linde, Adverse Effects of St. John???s Wort, The Journal of Clinical Psychiatry, vol.65, issue.11, pp.1470-1479, 2004.
DOI : 10.4088/JCP.v65n1105

K. A. Kobak, L. V. Taylor, A. Bystrisky, C. J. Kohlenberg, J. H. Greist et al., St John??s wort versus placebo in obsessive???compulsive disorder: results from a double-blind study, International Clinical Psychopharmacology, vol.20, issue.6, pp.299-304, 2005.
DOI : 10.1097/00004850-200511000-00003

J. Klein, NMDA Receptor-Antagonistic Properties of Hyperforin

. St, John's Wort, J Pharmacol Sci, vol.102, pp.47-54, 2006.

S. Lawvere, M. Mahoney, and . St, John's Wort. American Family Physician, pp.2249-2254, 2005.

Y. Lecrubier, G. Clerc, R. Didi, and M. Kieser, Efficacy of St. John???s Wort Extract WS 5570 in Major Depression: A Double-Blind, Placebo-Controlled Trial, American Journal of Psychiatry, vol.159, issue.8, pp.1361-1366, 2002.
DOI : 10.1176/appi.ajp.159.8.1361

P. Lefrançois and F. Et-ruby, Passeport-sante.net, 2010.

K. Linde, M. Berner, M. Egger, and C. Mulrow, Conclusions, British Journal of Psychiatry, vol.186, issue.02, pp.99-107, 2005.
DOI : 10.1192/bjp.186.2.99

K. Linde, M. Berner, and L. Kriston, St John's wort for major depression (Review). The Cochrane Library, pp.1-103, 2009.

K. Linde and . St, John's Wort ? an Overview, Forsch Komplementmed, vol.16, pp.146-155, 2009.
DOI : 10.1159/000209290

. St, John's wort ineractions, Eur J Clin Pharmacol, vol.62, pp.225-233, 2006.

J. Markowitz, J. Donovan, L. Devane, and C. , Effect of St John's Wort on Drug Metabolism by Induction of Cytochrome P450 3A4 Enzyme, JAMA, vol.290, issue.11, pp.1500-1504, 2003.
DOI : 10.1001/jama.290.11.1500

. Undeclared-exposure and . St, John's wort in hospitalized patients, Br J Clin Pharmacol, vol.58, pp.437-441, 2004.

R. Mathijssen, J. Verweij, P. Bruijn, J. Loos, and A. Sparreboom, Effects of St

I. Wort-on and . Metabolism, Journal of the National Cancer Institute, pp.1247-1249, 2002.

B. Nikolau, Identification of light-independent inhibition of human immunodeficiency virus-I infection through bioguided fractionation of Hypericum perforatum, pp.1-12, 2009.

J. Melzer, R. Brignoli, M. Keck, and R. Saller, A Hypericum Extract in the Treatment of Depressive Symptoms in Outpatients: An Open Study, Forschende Komplement??rmedizin / Research in Complementary Medicine, vol.17, issue.1, pp.7-14, 2010.
DOI : 10.1159/000277628

É. Millepertuis and . Dépressifs, La revue Prescrire, pp.362-369, 2004.

J. Morel, Phytothérapie et troubles psychiatriques : possibilités d'application avec le Millepertuis, La Phytothérapie Européenne. Novembre/Décembre, pp.8-14, 2005.

R. Moreno, C. Teng, K. De-almeida, and H. Junior, Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample, Revista Brasileira de Psiquiatria, vol.334, issue.8, pp.29-32, 2005.
DOI : 10.1111/j.1600-0447.1987.tb10566.x

M. Moretti, A. Maxson, F. Hanna, and G. Koren, Evaluating the safety of St

S. Mueller, J. Majcher-peszynska, R. Mundkowski, B. Uehleke, S. Klammt et al., No clinically relevant CYP3A induction after St. John???s wort with low hyperforin content in healthy volunteers, European Journal of Clinical Pharmacology, vol.73, issue.1, pp.81-87, 2009.
DOI : 10.1016/S1086-5802(16)31280-3

URL : https://hal.archives-ouvertes.fr/hal-00477921

H. Niederhofer, St John's Wort treating patients with autistic disorder, Phytotherapy Research, vol.40, issue.11
DOI : 10.1001/archpsyc.1983.01790100074010

. Oligosante, Laboratoires Oligosanté, 2010.

R. Rahimi, S. Nikfar, and M. Abdollahi, Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.33, issue.1, pp.118-127, 2009.
DOI : 10.1016/j.pnpbp.2008.10.018

F. Ruby, Passeport-sante.net, 2010.

S. Saeed, R. Bloch, and D. Antonacci, Herbal and Dietary Supplements for Treatment of Anxiety Disorders. American Academy of Family Physicians, pp.549-556, 2007.

A. Saxena, K. Tripathi, S. Roy, F. Khan, and A. Sharma, Pharmacovigilance: Effects of herbal components on human drugs interactions involving Cytochrome P450, Bioinformation, vol.3, issue.5
DOI : 10.6026/97320630003198

P. Smith, J. Bullock, B. Booker, C. Haas, C. Berenson et al., Induction of imatinib metabolism by hypericum perforatum, Blood, vol.104, issue.4, pp.1229-1230, 2004.
DOI : 10.1182/blood-2004-04-1240

F. Subhan, N. Khan, and R. Sewell, ), Phytotherapy Research, vol.10, issue.4, pp.564-571, 2009.
DOI : 10.1007/BF02029331

A. Szegedi, R. Kohnen, A. Dienel, and M. Kieser, Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine, BMJ, vol.330, issue.7490, pp.503-507, 2005.
DOI : 10.1136/bmj.38356.655266.82

L. H. Taylor and K. A. Kobak, An Open-Label Trial of St. John's Wort (Hypericum perforatum) in Obsessive-Compulsive Disorder, The Journal of Clinical Psychiatry, vol.61, issue.8, pp.575-578, 2000.
DOI : 10.4088/JCP.v61n0806

V. Poupelos and J. Millepertuis, Deuxièmes journées de l'AFSSAPS, 2004.

E. U. Vorbach, K. H. Arnoldt, and W. D. Hubner, Efficacy and Tolerability of St. John's Wort Extract LI 160 Versus Imipramine in Patients with Severe Depressive Episodes According to ICD-10, Pharmacopsychiatry, vol.30, issue.S 2, pp.81-85, 1997.
DOI : 10.1055/s-2007-979524

M. Wenk, L. Todescu, and S. Krähenbühl, Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females, British Journal of Clinical Pharmacology, vol.63, issue.4, pp.495-499, 2004.
DOI : 10.1016/S0009-9236(03)00187-5

E. Whiskey, U. Werneke, and D. Taylor, A systematic review and meta-analysis of

D. Whitten, S. Myers, J. Hawrelak, and H. Wohlmuth, The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials, British Journal of Clinical Pharmacology, vol.67, issue.5, pp.512-526, 2006.
DOI : 10.1067/mcp.2002.124080

. Wikipédia, Bienvenue sur Wikipedia. http://fr.wikipedia.org/wiki/Hypericum_Perforatum Wikipédia, Bienvenue sur Wikipédia, 2010.

/. Wikipédiawiki, L. Will-shahab, S. Bauer, U. Kunter, I. Roots et al., Bienvenue sur Wikipédia, 2010.

H. Woelk, Comparison of St John's wort and imipramine for treating depression: randomised controlled trial, BMJ, vol.321, issue.7260, pp.536-539, 2000.
DOI : 10.1136/bmj.321.7260.536

M. Wonnemann, A. Singer, and W. Müller, Inhibition of Synatosomal Uptake of 3 H-Lglutamate and 3 H-GABA by Hyperforin, a Major Constituent of St. John's Wort : The Role of Amiloride Sensitive Sodium Conductive Pathways

J. Zahlka, Les Plantes en Pharmacie Propriétés et utilisation, pp.136-167, 2005.

S. Petrovic, Evaluation of Hypericum perforatum Oil Extracts for an Antiinflammatory and Gastroprotective Activity in Rats, Phytother. Res, vol.23, pp.1559-1564, 2009.